Anti-glycoprotein Ib causes platelet aggregation: Different effects of blocking glycoprotein Ib and glycoprotein IIb/IIIa in the high shear filterometer

Blood Coagulation and Fibrinolysis

Volumn 9, Issue 6, 1998, Pages 453-461

  O'Brien, J R ^a   Etherington, M D ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Antibodies; Disaggregation; Filtration pressure; Platelet aggregation; Platelet membrane glycoproteins

Indexed keywords

AURINTRICARBOXYLIC ACID; CALCIUM ION; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOCALICIN; GLYCOPROTEIN IB; PROTEIN ANTIBODY; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; FEMALE; FILTER; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SHEAR RATE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; THROMBUS;

EID: 0031764445     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199809000-00001     Document Type: Article

References (43)

1. Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Araki Y, et al. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991; 87: 1234-1240.
2. Giorgio TD, Hellums JD. A cone and plate viscometer for the continuous measurement of blood platelet activation. Biorheology 1988; 25: 605-624.
3. Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc Res 1973; 5: 167-179.
4. O'Brien JR, Salmon GP. Shear stress activation of platelet glycoprotein IIb/IIIa plus von Willebrand factor causes aggregation: filter blockage and the long bleeding time in von Willebrand's disease. Blood 1987; 70: 1354-1361.
5. Chow TW, Hellums JD, Moake JL, Kroll MH. Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation. Blood 1992; 80: 113-120.
6. Ikeda Y, Handa M, Kamata T, Kawano K, Kawai Y, Watanabe K, et al. Transmembrane calcium influx associated with von Willebrand factor binding to GP Ib in the initiation of shear-induced platelet aggregation. Thromb Haemost 1993; 69: 496-502.
7. O'Brien JR, Etherington MD, Salmon GP, Ruggeri Z. The value of measuring shear-induced platelet aggregation in whole blood in a filter device [abstract]. Thromb Haemost 1991; 65: 1032.
8. O'Brien JR. Molecular biology of platelet retention in a high shear filter system [abstract]. Thromb Haemost 1993; 69: 1334.
9. O'Brien JR, Etherington MD. 'Rebleeding' the reversal of shear stress activation of platelets - a possible clue to thrombogenesis. Thromb Res 1992; 65: 821-822.
10. O'Brien JR, Etherington MD. High shear-induced platelet activation and inactivation: the importance of methodology. Blood Coag Fibrinol 1996; 7: 228-232.
11. Handa M, Titani K, Holland LZ, Roberts JR, Ruggeri ZM. The von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. Characterization by monoclonal antibodies and partial amino acid sequence analysis of proteolytic fragments. J Biol Chem 1986; 261: 12579-12585.
12. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. Blood 1983; 61: 99-110.
13. Phillips MD, Moake JL, Nolasco L, Turner N. Aurin tricarboxylic acid: a novel inhibitor of the association of von Willebrand factor and platelets. Blood 1988; 72: 1898-1903.
14. Bessos H, Murphy WG, Seghatchian MJ. Monitoring the release of glycocalicin in platelet concentrates by ELISA. Blood Coag Fibrinol 1991; 2: 373-376.
15. Niiya K, Hodson E, Bader R, Byers-Ward V, Koziol JA, Plow EF, et al. Increased surface expression of the membrane glycoprotein IIb/IIIa complex induced by platelet activation. Relationship to the binding of fibrinogen and platelet aggregation. Blood 1987; 70: 475-483.
16. Jones D, Fritschy J, Garson J, Nokes TJ, Kemshead JT, Hardisty RM. A monoclonal antibody binding to human medulloblastoma cells and to the platelet glycoprotein IIb/IIIa complex. Br J Haematol 1984; 57: 621-631.
17. Girma JP, Takahashi Y, Yoshioka A, Diaz J, Meyer D. Ristocetin and botrocetin involve two distinct domains of von Willebrand factor for binding to platelet membrane glycoprotein Ib. Thromb Haemost 1990; 64: 326-332.
18. Sugimoto M, Ricca G, Hrinda ME, Schreiber AB, Searfoss GH, Bottini E, et al. Functional modulation of the isolated glycoprotein Ib binding domain of von Willebrand factor expressed in Escherichia coli. Biochemistry 1991; 30: 5202-5209.
19. Alevriadou BR, Moake JL, Turner NA, Ruggeri ZM, Folie BJ, Phillips MD, et al. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood 1993; 81: 1263-1276.
20. Hanson SR. Platelet-specific antibodies as in vivo therapeutic reagents: a baboon model. In: Kunicki TJ, George JN (editors): Platelet immunobiology: molecular and clinical aspects. Philadelphia: Lippincott; 1989. p. 471.
21. Guo Z, Weinstein MJ, Phillips MD, Kroll MH. M(r) 6,400 aurin tricarboxylic acid directly activates platelets. Thromb Res 1993; 71: 77-88.
22. Girma JP, Ribba AS, Meyer D. Structure-function relation-ship of the A1 domain of von Willebrand factor. Thromb Haemost 1995; 74: 156-160.
23. Konstantopoulos K, Chow TW, Turner NA, Hellums JD, Moake JL. Shear stress-induced binding of von Willebrand factor to platelets. Biorheology 1997; 34: 57-71.
24. Coller BS, Anderson K, Weisman HF. New antiplatelet agents: platelet GpIIb/IIIa antagonists. Thromb Haemost 1995; 74: 302-308.
25. 3 integrins in hemostasis and vascular biology. Thromb Haemost 1995; 74: 149-155.
26. Pareti FI, Cattaneo M, Carpinelli L, Zighetti ML, Bressi C, Mannucci PM, et al. Evaluation of the abnormal platelet function in von Willebrand disease by the blood filtration test. Thromb Haemost 1996; 76: 460-468.
27. Salmon GP. Filter blockage by human blood under conditions of shear stress. Thesis: MPhil; 1989 for the Council for National Academic Awards.
28. Berliner S, Niiya K, Roberts JR, Houghten RA, Ruggeri ZM. Generation and characterization of peptide-specific antibodies that inhibit von Willebrand factor binding to glycoprotein IIb/IIIa without interacting with other adhesive molecules. Selectivity is conferred by Pro1743 and other amino acid residues adjacent to the sequence Arg1744-Gly1745-Asp1746. J Biol Chem 1988; 263: 7500-7505.
29. Lombardo VT, Hodson E, Roberts JR, Kunicki TJ, Zimmerman TS, Ruggeri ZM. Independent modulation of von Willebrand factor and fibrinogen binding to the platelet membrane glycoprotein IIb/IIIa complex as demonstrated by mono-clonal antibody. J Clin Invest 1985; 76: 1950-1958.
30. Brass LF, Shattil SJ, Kunicki TJ, Bennett JS. Effect of calcium on the stability of the platelet membrane glycoproteins IIb-IIIa complex. J Biol Chem 1985; 260: 7875-7881.
31. Fowler WE, Fretto LJ, Hamilton KK, Erickson HP, McKee PA. Substructure of human von Willebrand factor. J Clin Invest 1985; 76: 1491-1500.
32. Siedlecki CA, Lestini BJ, Kottke-Marchant K, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996; 88: 2939-2950.
33. Tsuji S, Sugimoto M, Kuwahara M, Nishio K, Takahashi Y, Fujimura Y, et al. Role and initiation mechanism of the interaction of glycoprotein Ib with surface-immobilized von Willebrand factor in a solid-phase platelet cohesion process. Blood 1996; 88: 3854-3861.
34. 3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J Biol Chem 1992; 267: 11300-11306.
35. Fernandez MFL, Ginsberg MH, Ruggeri ZM, Batlle FJ, Zimmerman TS. Multimeric structure of platelet factor V111/von Willebrand factor: the presence of larger multimers and their reassociation with thrombin-stimulated platelets. Blood 1982; 60: 1132-1138.
36. O'Brien JR, Etherington MD. Another antithrombotic action of aspirin. Thromb Res 1995; 80: 185-188.
37. Pasche B, Ouimet H, Francis S, Loscalzo J. Structural changes in platelet glycoprotein IIb/IIIa by plasmin: determinants and functional consequences. Blood 1994; 83: 404-414.
38. Folts JD, Crowell EB, Jr, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365-370.
39. Heynen HFG, Lozano Molero M, De Groot PG, Nieuwenhuis HK, Sixma JJ. Absence of ligands bound to glycoprotein IIb/IIIa on the exposed surface of a thrombus may limit thrombus growth in flowing blood. J Clin Invest 1994; 94: 1098-1112.
40. Coller BS, Kutok JL, Scudder LE, Galanakis DK, West SM, Rudomen GS, Springer KT. Studies of activated GpIIb/IIIa receptors on the luminal surface of adherent platelets: paradoxical loss of luminal receptors when platelets adhere to high density fibrinogen. J Clin Invest 1993; 92: 2796-2806.
41. Badimon L, Badimon JJ, Galvez A, Chesebro JH, Fuster V. Influence of arterial damage and wall shear rate on platelet deposition. Ex vivo study in a swine model. Arteriosclerosis 1986; 6: 312-320.
42. Clemetson KJ. Platelet activation: signal transduction via membrane receptors. Thromb Haemost 1995; 74: 111-116.
43. 3 and platelet function. Thromb Haemost 1997; 78: 96-100.